Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna K Dewan

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Dermatologic Clinics|August 31, 2019
Kaposi Sarcoma UpdatesShervin A Etemad, Anna K Dewan
Cutis|November 4, 2021
Business Education in Dermatology Residency: A Survey of Program DirectorsJames Randall Patrinely, Anna K Dewan
Journal of the American Academy of Dermatology|June 7, 2020
The modern dermatology program director: A cross-sectional study on personal and professional characteristicsJ Randall Patrinely, Anna K Dewan
Journal of the American Academy of Dermatology|April 23, 2023
Drug-induced suppression of HbA1C in dermatologyEva Rawlings Parker, Anna K Dewan
JAMA Oncology|September 27, 2019
Longer Survival With Anti-Programmed Cell Death 1 and Development of Cutaneous Toxic Effects, an Expected Association-In ReplyDouglas B Johnson, Fei Ye, Anna K Dewan
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 25, 2020
The Role of Anti-PD-1/PD-L1 in the Treatment of Skin CancerJames Randall Patrinely, Anna K Dewan, Douglas B Johnson
Journal of the American Academy of Dermatology|November 15, 2020
Impact of the COVID-19 pandemic on inpatient dermatology consult patterns at a tertiary care hospital: A retrospective cohort studyMeredith C Rogers, Matthew M Wallace, Lee Wheless, et al.
Immunology and Allergy Clinics of North America|April 26, 2022
Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and ModelsBenjamin C Park, Cosby A Stone, Anna K Dewan, et al.
JAMA Dermatology|March 30, 2017
Rituximab Treatment of Nivolumab-Induced Bullous PemphigoidLaura Sowerby, Anna K Dewan, Scott Granter, et al.
JAAD Case Reports|October 25, 2019
Nonbullous pemphigoid secondary to PD-1 inhibitionSean Singer, Caroline A Nelson, Christian G Lian, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Dermatologic Clinics|August 31, 2019
Kaposi Sarcoma UpdatesShervin A Etemad, Anna K Dewan
Cutis|November 4, 2021
Business Education in Dermatology Residency: A Survey of Program DirectorsJames Randall Patrinely, Anna K Dewan
Journal of the American Academy of Dermatology|June 7, 2020
The modern dermatology program director: A cross-sectional study on personal and professional characteristicsJ Randall Patrinely, Anna K Dewan
Journal of the American Academy of Dermatology|April 23, 2023
Drug-induced suppression of HbA1C in dermatologyEva Rawlings Parker, Anna K Dewan
JAMA Oncology|September 27, 2019
Longer Survival With Anti-Programmed Cell Death 1 and Development of Cutaneous Toxic Effects, an Expected Association-In ReplyDouglas B Johnson, Fei Ye, Anna K Dewan
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 25, 2020
The Role of Anti-PD-1/PD-L1 in the Treatment of Skin CancerJames Randall Patrinely, Anna K Dewan, Douglas B Johnson
Journal of the American Academy of Dermatology|November 15, 2020
Impact of the COVID-19 pandemic on inpatient dermatology consult patterns at a tertiary care hospital: A retrospective cohort studyMeredith C Rogers, Matthew M Wallace, Lee Wheless, et al.
Immunology and Allergy Clinics of North America|April 26, 2022
Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and ModelsBenjamin C Park, Cosby A Stone, Anna K Dewan, et al.
JAMA Dermatology|March 30, 2017
Rituximab Treatment of Nivolumab-Induced Bullous PemphigoidLaura Sowerby, Anna K Dewan, Scott Granter, et al.
JAAD Case Reports|October 25, 2019
Nonbullous pemphigoid secondary to PD-1 inhibitionSean Singer, Caroline A Nelson, Christian G Lian, et al.
Pageof 4